| 前收市價 | 40.69 |
| 開市 | 40.55 |
| 買盤 | 40.51 x 1000 |
| 賣出價 | 42.15 x 900 |
| 今日波幅 | 40.10 - 41.29 |
| 52 週波幅 | 13.46 - 62.21 |
| 成交量 | |
| 平均成交量 | 1,359,480 |
| 市值 | 3.635B |
| Beta 值 (5 年，每月) | 無 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -5.80 |
| 業績公佈日 | 無 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 59.63 |
InvestorPlace3 Biotech Stocks to Buy on the Dip: April 2024
If you follow Warren Buffett’s advice of being greedy when others are fearful, then it probably makes sense to consider biotech stocks to buy on the dip. Primarily, the thesis centers on the underlying necessity of the ecosystem. While humans have made incredible innovations in the digital realm, those don’t mean a whole lot if we succumb to various diseases and conditions. So, from the standpoint of social progress, the biotechnology sector is critical. Moreover, the industry may be somewhat in
InvestorPlaceStocks to Watch: 3 Companies Working on Next-Gen Weight Loss Drugs
Everyone knows that America has a major obesity problem. Because of this, new anti-obesity drugs are going to generate a great deal of revenue and profits their companies. What people don’t realize is that those weight-loss drugs come with high valuations and equities that reflect most of the profits they will generate. Consequently, investing in firms with lower valuations that are focused on improving or developing superior weight-loss treatments is a better way to go. Here are three weight-lo
